An antisense oligonucleotide targeting the growth hormone receptor inhibits neovascularization in a mouse model of retinopathy

Molecular Vision

Volumn 13, Issue , 2007, Pages 1529-1538

  Wilkinson Berka, Jennifer L ^a   Lofthouse, Shari ^b   Jaworski, Kassie ^a   Ninkovic, Slavisa ^a   Tachas, George ^b   Wraight, Christopher J ^b  

^a MONASH UNIVERSITY   (Australia)

^b Antisense Therapeutics Ltd   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ATL 227446; ATL 260120; ATL 261303; GROWTH HORMONE RECEPTOR; OCTREOTIDE; OXYGEN; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

AMBIENT AIR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; EARLY INTERVENTION; FEMALE; HISTOPATHOLOGY; MOUSE; NONHUMAN; PERINATAL PERIOD; PRIORITY JOURNAL; PROTEIN TARGETING; RETINA BLOOD FLOW; RETINA BLOOD VESSEL; RETINA NEOVASCULARIZATION; RETINOPATHY; THERAPY DELAY;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; OCTREOTIDE; OLIGONUCLEOTIDES, ANTISENSE; OXYGEN; RECEPTORS, SOMATOTROPIN; RETINAL DISEASES; RETINAL VESSELS;

EID: 34548445134     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Klein R, Klein BE, Moss SE. Epidemiology of proliferative diabetic retinopathy. Diabetes Care 1992; 15:1875-91.
2. Smith LE. Pathogenesis of retinopathy of prematurity. Growth Horm IGF Res 2004; 14:S140-4.
3. Alzaid AA, Dinneen SF, Melton LJ 3rd, Rizza RA. The role of growth hormone in the development of diabetic retinopathy. Diabetes Care 1994; 17:531-4.
4. Kohner EM, Joplin GF, Blach RK, Cheng H, Fraser TR. Pituitary ablation in the treatment of diabetic retinopathy. (A randomized trial). Trans Ophthalmol Soc U K 1972; 92:79-90.
5. Lundbaek K, Christensen NJ, Jensen VA, Johansen K, Olsen TS, Hansen AP, Orskov H, Osterby R. Diabetes, diabetic angiopathy, and growth hormone. Lancet 1970; 2:131-3.
6. Wright AD, McLachlan MS, Doyle FH, Fraser TR. Serum growth hormone levels and size of pituitary tumour in untreated acromegaly. Br Med J 1969; 4:582-4.
7. Merimee TJ. A follow-up study of vascular disease in growth-hormone-deficient dwarfs with diabetes. N Engl J Med 1978; 298:1217-22.
8. Hansen R, Koller EA, Malozowski S. Full remission of growth hormone (GH)-induced retinopathy after GH treatment discontinuation: long-term follow-up. J Clin Endocrinol Metab 2000; 85:2627.
9. Smith LE, Kopchick JJ, Chen W, Knapp J, Kinose F, Daley D, Foley E, Smith RG, Schaeffer JM. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 1997; 276:1706-9.
10. Kohner EM, Oakley NW. Diabetic retinopathy. Metabolism 1975; 24:1085-102.
11. Growth Hormone Antagonist for Proliferative Diabetic Retinopathy Study Group. The effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy. Ophthalmology 2001; 108:2266-72.
12. Higgins RD, Yan Y, Schrier BK. Somatostatin analogs inhibit neonatal retinal neovascularization. Exp Eye Res 2002; 74:553-9.
13. Tachas G, Lofthouse S, Wraight CJ, Baker BF, Sioufi NB, Jarres RA, Berdeja A, Rao AM, Kerr LM, d'Aniello EM, Waters MJ. A GH receptor antisense oligonucleotide inhibits hepatic GH receptor expression, IGF-I production and body weight gain in normal mice. J Endocrinol 2006; 189:147-54.
14. Wilkinson-Berka JL, Alousis NS, Kelly DJ, Gilbert RE. COX-2 inhibition and retinal angiogenesis in a mouse model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 2003; 44:974-9.
15. Penn JS, Tolman BL, Lowery LA. Variable oxygen exposure causes preretinal neovascularization in the newborn rat. Invest Ophthalmol Vis Sci 1993; 34:576-85.
16. Moravski CJ, Kelly DJ, Cooper ME, Gilbert RE, Bertram JF, Shahinfar S, Skinner SL, Wilkinson-Berka JL. Retinal neovascularization is prevented by blockade of the renin-angiotensin system. Hypertension 2000; 36:1099-104.
17. Wilkinson-Berka JL, Babic S, De Gooyer T, Stitt AW, Jaworski K, Ong LG, Kelly DJ, Gilbert RE. Inhibition of platelet-derived growth factor promotes pericyte loss and angiogenesis in ischemic retinopathy. Am J Pathol 2004; 164:1263-73.
18. Zhang H, Cook J, Nickel J, Yu R, Stecker K, Myers K, Dean NM. Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis. Nat Biotechnol 2000; 18:862-7.
19. Crooke RM, Graham MJ, Lemonidis KM, Whipple CP. Koo S, Perera RJ. An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J Lipid Res 2005; 46:872-84.
20. Crooke ST. Progress in antisense technology. Annu Rev Med 2004; 55:61-95.
21. Le Roith D, Bondy C, Yakar S, Liu JL, Butler A. The somatomedin hypothesis: 2001. Endocr Rev 2001; 22:53-74.
22. Bertherat J, Bluet-Pajot MT, Epelbaum J. Neuroendocrine regulation of growth hormone. Eur J Endocrinol 1995; 132:12-24.
23. Hellstrom A, Perruzzi C, Ju M, Engstrom E, Hard AL, Liu JL, Albertsson-Wikland K, Carlsson B, Niklasson A, Sjodell L, LeRoith D, Senger DR, Smith LE. Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc; Natl Acad Sci U S A 2001; 98:5804-8.
24. Lineham JD, Smith RM, Dahlenburg King RA, Haslam RR, Stuart MC, Faull L. Circulating insulin-like growth factor I levels in newborn premature and full-term infants followed longitudinally. Early Hum Dev 1986; 13:37-46.
25. Bona G, Aquili C, Ravanini P, Gallina MR, Cigolotti AC, Zaffaroni M, Paniccia P, Mussa F. Growth hormone, insulin-like growth factor-I and somatostatin in human fetus, newborn, mother plasma and amniotic fluid. Panminerva Med 1994; 36:5-12.
26. Hellstrom A, Svensson E, Carlsson B, Niklasson A, Albertsson-Wikland K. Reduced retinal vascularization in children with growth hormone deficiency. J Clin Endocrinol Metab 1999; 84:795-8.
27. Ashton N. Donders lecture, 1967. Some aspecrs of the comparative pathology of oxygen toxicity in the retina. Br J Ophthalmol 1968; 52:505-31.
28. Stone J, Itin A, Alon T, Pe'er J, Gnessin H, Chan-Ling T, Keshet E. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci 1995; 15:4738-47.
29. McKenna DJ, Simpson DA, Feeney S, Gardiner TA, Boyle C, Nelson J, Stitt AW. Expression of the 67 kDa laminin receptor (67LR) during retinal development: correlations with angiogenesis. Exp Eye Res 2001; 73:81-92.
30. Mallet B, Vialettes B, Haroche S, Escoffier P, Gastaut P, Taubert JP, Vague P. Stabilization of severe proliferative diabetic retinopathy by long-term treatment with SMS 201-995. Diabete Metab 1992; 18:438-44.
31. Boehm BO, Lang GK, Jehle PM, Feldman B, Lang GE. Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy. Horm Metab Res 2001; 33:300-6.
32. Grant MB, Mames RN, Fitzgerald C, Hazariwala KM, Cooper-DeHoff R, Caballero S, Estes KS. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care 2000, 23:504-9.
33. McIxod DS, Taomoto M, Cao J, Zhu Z, Witte L, Lutty GA. Localization of VEGF receptor-2 (KDR/Flk-1) and effects of blocking it in oxygen-induced retinopathy. Invest Ophthalmol Vis Sci 2002; 43:474-82.
34. Banin E, Dorrell MI, Aguilar E, Ritter MR, Aderman CM, Smith AC, Friedlander J, Friedlander M. T2-TrpRS inhibits preretinal neovascularization and enhances physiological vascular re-growth in OIR as assessed by a new method of quantification. Invest Ophthalmol Vis Sci 2006; 47:2125-34.
35. Gardiner TA, Gibson DS, de Gooyer TE, de la Cruz VF, McDonald DM, Stitt AW, Inhibition of tumor necrosis factor-alpha improves physiological angiogenesis and reduces pathological neovascularization in ischemic retinopathy. Am J Pathol 2005; 166:637-44.
36. Hartnett ME, Martiniuk DJ, Saito Y, Geisen P, Peterson LJ. McColm JR. Triamcinolone reduces neovascularization, capillary density and IGF-1 receptor phosphorylation in a model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci 2006; 47:4975-82.